SEC Form 4 · accession 0000950138-17-000319
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Harbaugh
Officer — Exec. VP & CFO
Period of report
Mar 10, 2017
Accepted (ET)
Mar 14, 2017 · 8:40 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 10, 2017 | P | 600 | $49.19 | A | 76,085 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $49.18 to $49.22, inclusive. Mr. Harbaugh will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the range.
- F2Includes 156 shares acquired on December 31, 2016, under the Mallinckrodt employee stock purchase plan.